• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

疾病复发期间HER2状态的变化预示原发性乳腺鳞状细胞癌预后良好：一例报告

Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: A case report.

作者信息

Cao Yong, Yue Yeli, Zhou Xin, Luo Jie, Zeng Xiaohua, Dong JuanHui, Liang Xinrui

机构信息

Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.

出版信息

Medicine (Baltimore). 2019 Mar;98(9):e14654. doi: 10.1097/MD.0000000000014654.

DOI:10.1097/MD.0000000000014654
PMID:30817587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6831174/
Abstract

RATIONALE

Primary squamous cell carcinoma (PSCC) of the breast is one of the least common types of breast cancer. Adjuvant treatment for PSCC remains an unresolved issue.

PATIENT CONCERNS

We reported a case of a 48-year-old postmenopausal female patients with a 2 × 2.5 cm lump presented with no symptoms.

DIAGNOSES

This patient was diagnosed as PSCC of the breast. The original tumor and first recurrence exhibited triple negative phenotype, whereas the second recurrence was HER2-positive.

INTERVENTIONS

A tumorectomy with latissimus dorsi flap reconstruction for the second recurrence was performed followed by targeted therapy with trastuzumab.

OUTCOMES

The patient had a complete remission, which was sustained over the 25 months of follow-up after the tumorectomy.

LESSONS

This is the first reported case in literature of a breast PSCC patient with switched immunohistochemical phenotypes during disease recurrence. Surgical resection with flap reconstruction and targeted therapy successfully treated the recurrence.

摘要

理论依据

乳腺原发性鳞状细胞癌（PSCC）是乳腺癌中最罕见的类型之一。PSCC的辅助治疗仍是一个未解决的问题。

患者情况

我们报告了一例48岁绝经后女性患者，有一个2×2.5厘米的肿块，无症状。

诊断

该患者被诊断为乳腺PSCC。原发肿瘤和首次复发表现为三阴性表型，而第二次复发为HER2阳性。

干预措施

对第二次复发进行了带背阔肌肌皮瓣重建的肿瘤切除术，随后用曲妥珠单抗进行靶向治疗。

结果

患者完全缓解，在肿瘤切除术后的25个月随访中病情持续缓解。

经验教训

这是文献中首次报道的一例乳腺PSCC患者在疾病复发期间免疫组化表型发生转变的病例。带肌皮瓣重建的手术切除和靶向治疗成功治疗了复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/b0d155f88e6a/medi-98-e14654-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/c3c52a4ddcf8/medi-98-e14654-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/0e736ae3eb36/medi-98-e14654-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/e54a0767c571/medi-98-e14654-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/99f0d49b61e8/medi-98-e14654-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/b0d155f88e6a/medi-98-e14654-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/c3c52a4ddcf8/medi-98-e14654-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/0e736ae3eb36/medi-98-e14654-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/e54a0767c571/medi-98-e14654-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/99f0d49b61e8/medi-98-e14654-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fe1/6831174/b0d155f88e6a/medi-98-e14654-g007.jpg

相似文献

1
Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: A case report.疾病复发期间HER2状态的变化预示原发性乳腺鳞状细胞癌预后良好：一例报告
Medicine (Baltimore). 2019 Mar;98(9):e14654. doi: 10.1097/MD.0000000000014654.
2
[Clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma of the breast].[乳腺化生性鳞状细胞癌的临床病理特征及HER2表达]
Zhonghua Bing Li Xue Za Zhi. 2022 Sep 8;51(9):843-849. doi: 10.3760/cma.j.cn112151-20220430-00356.
3
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.磷酸化HER2在接受辅助曲妥珠单抗治疗的HER2阳性乳腺癌患者中的预后价值。
Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.
4
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.人表皮生长因子受体 2 阳性导管原位癌患者后续原位和浸润性乳腺癌的风险。
Ann Oncol. 2015 Apr;26(4):682-687. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18.
5
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.曲妥珠单抗治疗后 HER2 阳性乳腺癌患者的 HER2 状态丢失及其预后
Ann Oncol. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7.
6
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.当患有三阴性乳腺癌时，一小部分但具有重要意义的患者仍然可以用抗 HER2 抑制剂靶向治疗。
J Cancer Res Clin Oncol. 2013 Sep;139(9):1563-8. doi: 10.1007/s00432-013-1479-0. Epub 2013 Jul 28.
7
Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.确认乳腺癌患者复发性病变中 HER2 过表达的重要性。
Breast Cancer. 2013 Oct;20(4):336-41. doi: 10.1007/s12282-012-0341-6. Epub 2012 Feb 25.
8
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.预测雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌早期和晚期远处复发的临床病理因素
Breast Cancer. 2016 Nov;23(6):830-843. doi: 10.1007/s12282-015-0649-0. Epub 2015 Oct 14.
9
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.曲妥珠单抗辅助治疗后 HER2 阳性乳腺癌患者的晚期复发发生率：NCCTG N9831（Alliance）与 NRG 肿瘤学/NSABP B-31 的联合分析
J Clin Oncol. 2019 Dec 10;37(35):3425-3435. doi: 10.1200/JCO.19.00443. Epub 2019 Oct 17.
10
Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.接受辅助性曲妥珠单抗治疗的HER2阳性早期乳腺癌患者：临床病理特征、疗效及影响生存的因素。
Asian Pac J Cancer Prev. 2015;16(4):1643-9. doi: 10.7314/apjcp.2015.16.4.1643.

引用本文的文献

1
A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast.1例罕见的HER2阳性乳腺纯化生鳞状细胞癌。
Discov Oncol. 2025 Jul 16;16(1):1340. doi: 10.1007/s12672-025-03107-9.
2
Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report.病例报告：阿帕替尼联合新辅助治疗原发性乳腺鳞状细胞癌：一例病例报告
Front Pharmacol. 2023 May 11;14:1115422. doi: 10.3389/fphar.2023.1115422. eCollection 2023.
3
Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.

本文引用的文献

1
Clinical features and treatment of squamous cell carcinoma of the breast.乳腺鳞状细胞癌的临床特征与治疗
Onco Targets Ther. 2016 May 27;9:3181-5. doi: 10.2147/OTT.S95128. eCollection 2016.
2
Squamous Cell Carcinoma In Situ of the Breast: Report of a Case.乳腺原位鳞状细胞癌：一例报告
Breast J. 2016 Sep;22(5):573-7. doi: 10.1111/tbj.12631. Epub 2016 Jun 8.
3
Immediate transverse rectus abdominis musculocutaneous flap reconstruction is associated with improved cancer-specific survival in locally advanced breast cancer.
初始分期为IV期乳腺癌的原发肿瘤切除术：重点关注程序性死亡配体1表达、启动子甲基化状态及生存情况。
Medicine (Baltimore). 2019 Aug;98(33):e16773. doi: 10.1097/MD.0000000000016773.
即刻横行腹直肌肌皮瓣重建与局部晚期乳腺癌患者癌症特异性生存率的提高相关。
Ann Plast Surg. 2014 Sep;73 Suppl 1:S31-6. doi: 10.1097/SAP.0000000000000251.
4
The integrated evaluation of the results of oncoplastic surgery for locally advanced breast cancer.局部晚期乳腺癌保乳整形术效果的综合评价。
Breast J. 2014 Jan-Feb;20(1):53-60. doi: 10.1111/tbj.12222. Epub 2013 Nov 18.
5
Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival.乳腺原发性鳞状细胞癌：局部区域复发和总生存的预测因素。
Am J Surg Pathol. 2013 Jun;37(6):867-73. doi: 10.1097/PAS.0b013e3182877569.
6
Primary pure squamous cell carcinoma of the breast might be sensitive to Cisplatin-based chemotherapy.原发性乳腺单纯鳞状细胞癌可能对基于顺铂的化疗敏感。
Case Rep Oncol. 2012 Sep;5(3):561-5. doi: 10.1159/000343745. Epub 2012 Oct 16.
7
Breast abscess as the initial manifestation of primary pure squamous cell carcinoma: a rare presentation and literature review.乳腺脓肿作为原发性单纯鳞状细胞癌的初始表现：一种罕见的病例展示及文献综述
Breast Dis. 2011;33(3):125-31. doi: 10.3233/BD-2012-0335.
8
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值：GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
9
Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women.东亚和东南亚女性乳腺癌发病率的最新趋势和模式。
Cancer Causes Control. 2010 Nov;21(11):1777-85. doi: 10.1007/s10552-010-9604-8. Epub 2010 Jun 18.
10
Cancer in Asia - Incidence rates based on data in cancer incidence in five continents IX (1998-2002).亚洲癌症——基于《五大洲癌症发病率IX（1998 - 2002）》数据的发病率
Asian Pac J Cancer Prev. 2010;11 Suppl 2:11-6.